News

Ligand is also entitled to future milestones and royalties from this antibody. WuXi Biologics was previously contracted by its Chinese partner Harbin Gloria Pharmaceuticals to discover and develop

The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. “Takeda’s extensive knowledge and expertise in

According to the drug makers, the PARP inhibitor has been approved as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer irrespective of

KAF156, which belongs to the class of the imidazolopiperazines, is a next-generation antimalarial compound that holds capability to treat drug-resistant strains of the malaria parasite. The trial was

The study will examine the effectiveness of PLX-R18 as a treatment for Acute Radiation Syndrome (ARS) prior to, and within the first 24 hours of exposure to radiation.

The financing was co-led by new investor Wellington Management Company LLP and by a large US-based, healthcare-focused fund, participating as an existing Atreca investor. Additional participation included new

The FDA assessed and approved Besponsa under the breakthrough therapy designation and priority review programs. Besponsa is a targeted therapy, which is believed to work by binding to B-cell

Based in Baltimore, Maryland, Insilico Medicine is an American biotechnology startup that uses AI research for drug discovery, aging research and biomarker development. The collaboration to discover novel biological

This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation. Evotec paid a total consideration of